This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Enzastaurin

Denovo Biopharma

Drug Names(s): LY317615

Description: LY317615 (Enzastaurin) is an orally available potent inhibitor of Protein Kinase C beta. The beta isoform lies in the signal cascade of VEGF and inhibition of this pathway may lead to a block in tumor angiogenesis and growth.

In addition to blocking PKC beta, LY317615 has shown inhibitory activity of other intracellular signaling proteins that are important to the regulation of cellular proliferation and apoptosis, including the Akt pathway. Furhtermore, at concentrations that are reached or exceeded in clinical trials, LY317615 was shown to inhibit the activity of other PKC isoforms in addition to PKC beta.

Deal Structure: Eli Lilly and Denovo
In September 2014, Denovo announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. enovo plans to screen for appropriate patient subsets for enrollment in future clinical trials that the company plans to conduct.


Enzastaurin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug